思美泰联合阿拓莫兰治疗酒精性肝病疗效观察

Curative Observation on Alcohol Hepatopathy Treated with Simeitai and Atuomolan

目的 探讨思美泰与阿拓莫兰联合治疗酒精性肝病的疗效。方法 选择 32例酒精性肿瘤 (包括酒精性脂肪肝、酒精性肝炎和酒精性肝硬化 )做为治疗组 ,采用思美泰 1 0g ,1次 /d静点 ;阿拓莫兰 1 2g ,1次 /d静点 ,30d为 1疗程。另选择 31例酒精性肝病为对照组 ,给予门冬氨酸钾镁 30mL加能量合剂 1支 ,维生素C 2 0g ,1次 /d静点 ,30d为 1疗程。观测ALT、AST、TBIL、GGT等主要指标。结果 治疗组显效 10例 ,有效 19例 ,无效 3例 ,总有效率 90 6 2 % ;对照组显效 6例 ,有效 16例 ,无效 9例 ,总有效率 70 96 % ,2组比较差异显著。结论 思美泰与阿拓莫兰联合治疗酒精性肝病 ,疗效显著 ,且无毒副反应。

Objective To discuss the curative effect on alcohol hepatopathy treated with simeitai and atuomolan. Methods 32 cases alcohol hepatopathy patient were chosen as therapy group treated with simeitai 1.0g i.v. /d and atuomolan 1.2g i.v./d for 30 days as a course. The other 31 cases alcohol hepatopathy patient were chosen as control group treated with potassium magnesium aspartape (PMA) and vitamin C. The ALT, AST, TBIL and GGT were observed. Results The total effective rate was 90.62% with the excellent effect 10 cases, good effect 19 cases and no effect 3 cases in therapy group. The total effective rate was 70.96% with the excellent effect 6 cases, good effect 16 cases and no effect 9 cases in control group. There was significant difference between two groups. Conclusion The combined treatment could obtain obvious curative effect without side effect.